Outcomes of treat & extend ranibizumab in diabetic macular oedema
Reviewed by Ed Rule

This study retrospectively evaluated 118 eyes of 87 patients who received ranibizumab in a treat and extend regimen for diabetic macular oedema (DMO). Data were collected for patients under follow-up for 24 months. After 24 months, patients gained a mean of 4.73 ETDRS letters. Central retinal thickness decreased by nearly 100µm. The authors also analysed patients’ OCTs and measured the amount of disruption to the inner segment / outer segment (IS/OS) junction. Logistic regression analysis found integrity of the IS/OS junction predicted resolution of DMO; the probability of having a dry macula at 24 months increased by 88% if the IS/OS junction was intact at baseline. This study is limited by its retrospective design and lack of a comparator group, but does support findings from previous studies (such as the RETAIN study) that a treat and extend regime can be a viable strategy for treating DMO.

Predictors for 2-year functional and morphological outcomes of a treat-and-extend regimen with ranibizumab in patients with diabetic macular edema.
Giannakaki-Zimmermann H, Behrndt A, Hoffmann L, et al.
OPHTHALMIC RESEARCH
2021;64(3):465-75.